These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 35300912)

  • 41. Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice.
    Fu EL; Clase CM; Janse RJ; Lindholm B; Dekker FW; Jardine MJ; Carrero JJ
    Int J Cardiol; 2022 Apr; 352():172-179. PubMed ID: 35074492
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life.
    Longato E; Di Camillo B; Sparacino G; Gubian L; Avogaro A; Fadini GP
    BMJ Open Diabetes Res Care; 2020 Jun; 8(1):. PubMed ID: 32591373
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis.
    Castellana M; Cignarelli A; Brescia F; Perrini S; Natalicchio A; Laviola L; Giorgino F
    Sci Rep; 2019 Dec; 9(1):19351. PubMed ID: 31852920
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lessons from bariatric surgery: Can increased GLP-1 enhance vascular repair during cardiometabolic-based chronic disease?
    Bakbak E; Terenzi DC; Trac JZ; Teoh H; Quan A; Glazer SA; Rotstein OD; Al-Omran M; Verma S; Hess DA
    Rev Endocr Metab Disord; 2021 Dec; 22(4):1171-1188. PubMed ID: 34228302
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recent trends in GLP-1 RA and SGLT2i use among people with type 2 diabetes and atherosclerotic cardiovascular disease in the USA.
    King A; Tan X; Dhopeshwarkar N; Bohn R; Dea K; Leonard CE; de Havenon A
    BMJ Open Diabetes Res Care; 2024 Oct; 12(5):. PubMed ID: 39366717
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of the blood pressure management between sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists.
    Kobayashi K; Toyoda M; Hatori N; Sakai H; Furuki T; Sato K; Terauchi Y; Tamura K; Kanamori A
    Sci Rep; 2022 Sep; 12(1):16106. PubMed ID: 36167964
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Possible Advantage of Glucagon-Like Peptide 1 Receptor Agonists for Kidney Transplant Recipients With Type 2 Diabetes.
    Sato T; Azuma Y; Ozone C; Okazaki M; Takeda A; Okada M; Futamura K; Hiramitsu T; Goto N; Narumi S; Watarai Y
    J Clin Endocrinol Metab; 2023 Sep; 108(10):2597-2603. PubMed ID: 36974363
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
    Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
    Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Potential unrealized mortality benefit of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transport-2 inhibitors: A report from the Veterans Health Administration Clinical Assessment, Reporting and Tracking program.
    Salahuddin T; Richardson V; McNeal DM; Henderson K; Hess PL; Raghavan S; Saxon DR; Valle JA; Waldo SW; Ho PM; Schwartz GG
    Diabetes Obes Metab; 2021 Jan; 23(1):97-105. PubMed ID: 32902128
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Glucagon-like peptide-1 agonists combined with sodium-glucose cotransporter-2 inhibitors reduce weight in type 1 diabetes.
    Al-Ozairi E; Irshad M; Taghadom E; Sojan L; Al Kandari J; Alroudhan D; le Roux CW
    Obesity (Silver Spring); 2023 Mar; 31(3):716-723. PubMed ID: 36811241
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities.
    Brown E; Wilding JPH; Barber TM; Alam U; Cuthbertson DJ
    Obes Rev; 2019 Jun; 20(6):816-828. PubMed ID: 30972878
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013-2018.
    Dave CV; Schneeweiss S; Wexler DJ; Brill G; Patorno E
    Diabetes Care; 2020 Apr; 43(4):921-924. PubMed ID: 32041899
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases.
    Xie Y; Bowe B; Gibson AK; McGill JB; Maddukuri G; Yan Y; Al-Aly Z
    Diabetes Care; 2020 Nov; 43(11):2859-2869. PubMed ID: 32938746
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sodium-Glucose Cotransporter-2 Inhibitors versus Glucagon-Like Peptide 1 Receptor Agonists Effects on Kidney and Clinical Outcomes in Veterans with Type 2 Diabetes.
    Morello CM; Awdishu L; Lam S; Heman A; Bounthavong M
    Kidney360; 2024 Nov; 5(11):1633-1643. PubMed ID: 39361784
    [No Abstract]   [Full Text] [Related]  

  • 55. Glucagon-Like Peptide 1 Receptor Agonists Versus Sodium-Glucose Cotransporter 2 Inhibitors for Atherosclerotic Cardiovascular Disease in Patients With Type 2 Diabetes.
    Yanai H; Adachi H; Hakoshima M; Katsuyama H
    Cardiol Res; 2023 Feb; 14(1):12-21. PubMed ID: 36896226
    [TBL] [Abstract][Full Text] [Related]  

  • 56. SGLT2 Inhibitor and GLP-1 Receptor Agonist Combination Therapy Substantially Improved the Renal Function in a Patient with Type 2 Diabetes: Implications for Additive Renoprotective Effects of the Two Drug Classes.
    Nonomura K; Iizuka K; Kuwabara-Ohmura Y; Yabe D
    Intern Med; 2020 Jun; 59(12):1535-1539. PubMed ID: 32188813
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.
    Cardoso P; Young KG; Nair ATN; Hopkins R; McGovern AP; Haider E; Karunaratne P; Donnelly L; Mateen BA; Sattar N; Holman RR; Bowden J; Hattersley AT; Pearson ER; Jones AG; Shields BM; McKinley TJ; Dennis JM;
    Diabetologia; 2024 May; 67(5):822-836. PubMed ID: 38388753
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association between glucagon-like peptide-1 receptor agonists and biliary-related diseases in patients with type 2 diabetes: A nationwide cohort study.
    Dong YH; Wu JH; Chang CH; Lin JW; Wu LC; Toh S
    Pharmacotherapy; 2022 Jun; 42(6):483-494. PubMed ID: 35508702
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Patient-perceived benefits and risks of off-label use of SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes: a structured qualitative assessment.
    Edwards K; Uruska A; Duda-Sobczak A; Zozulinska-Ziolkiewicz D; Lingvay I
    Ther Adv Endocrinol Metab; 2023; 14():20420188231180987. PubMed ID: 37440840
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study.
    Longato E; Di Camillo B; Sparacino G; Tramontan L; Avogaro A; Fadini GP
    Cardiovasc Diabetol; 2021 Nov; 20(1):222. PubMed ID: 34774054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.